Photo from Talha Badar/LinkedIn
Jun 16, 2024, 19:23
Talha Badar on Copland
Talha Badar shared a post on X:
“Copland: Targeting alternating pathway in CML/CML-AP/CML-BP.
1) MDM2i 2) BH3 mimetic 3) EZH2i
Conclusion:
- Despite potent TKIs, eliminating CML stem cells remains challenging.
- Need better strategies to manage CML-AP/BP with poor outcomes, mOS 6-12 months.”
Source: Talha Badar/X
Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 22, 2025, 09:26
Aug 22, 2025, 09:04
Aug 22, 2025, 08:53
Aug 22, 2025, 08:48
Aug 22, 2025, 08:24
Aug 22, 2025, 08:08
Aug 22, 2025, 07:33